What's Happening?
Thermo Fisher Scientific has announced a strategic collaboration with HealthVerity to enhance its real-world data capabilities. This partnership will provide Thermo Fisher's PPD clinical research business with access to HealthVerity's TaXOnomy claims
dataset, which includes data from over 270 million de-identified patient lives across the U.S. healthcare system. The collaboration aims to strengthen data-driven clinical development and evidence generation for biopharma sponsors. By integrating high-quality, linked healthcare data with AI-enabled analytics, Thermo Fisher aims to improve trial feasibility, optimization, recruitment, and real-world evidence generation. The agreement also grants access to a marketplace of over 70 curated data sources, including electronic medical records and laboratory results, enabling more precise site selection strategies and improved startup timelines.
Why It's Important?
This collaboration is significant for the biopharmaceutical industry as it enhances the ability to generate robust real-world evidence, which is crucial for clinical development and post-approval processes. By leveraging comprehensive datasets and AI analytics, Thermo Fisher can offer more precise and efficient clinical trial strategies, potentially reducing costs and improving patient outcomes. The partnership also supports Thermo Fisher's continued investment in digital innovation, positioning the company to deliver differentiated value while maintaining rigorous privacy protections and data governance standards. This move reflects a broader industry trend towards integrating real-world data and AI to enhance clinical research and development, ultimately benefiting biopharma sponsors and patients.
